An exploratory real world study on pharmacoeconomic evaluation of Huatuo Zaizao Pills in the treatment of acute ischemic stroke and the prevention and treatment of cognitive impairment

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2200005808

Enrollment

Unknown

Registered

2022-04-04

Start date

2022-03-21

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral ischemic stroke

Interventions

Non-exposure group:Treated with normal medicine

Exposure group :Treated with normal medicine+Oral Huatuo Zaizao Pills

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Course of disease =30 days; (2)There was no disability before the onset of the disease; (3)No senile dementia was diagnosed before enrollment; (4)4 points <NIHSS = 20 points at enrollment.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Infarction rate again;Disabled rate;Pharmacoeconomic indicators;Safety evaluation index;All-cause and attributable mortality rates;Changes in hippocampal volume;Incidence of cognitive impairment;Changes in NHISS scores;Changes in cognitive impairment scores;Changes in white matter injury scale score;Incidence of acute cardiovascular and cerebrovascular events;	—

Countries

China

Contacts

Public ContactYun Xu

danting@163.com15950522505

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026